Richard Schwartz | Immunology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

         Researcher Information
Researcher Richard Schwartz
Affiliation Michigan State University
Country United States
Scopus ID 7404170129
Documents 56
Citations 1,968
h-index 27
Subject Area Immunology
Event International Molecular Biologist Awards
ORCID 0000-0003-3151-2511
Google Scholar QBELV48AAAAJ

Richard Schwartz

Michigan State University, United States

Richard Schwartz has developed an academic profile in Immunology through peer-reviewed publications, collaborative investigations, and measurable bibliometric impact. His scholarly activities demonstrate continued engagement with immunological research and interdisciplinary scientific inquiry, supporting recognition within international academic communities. The Innovative Research Award recognizes distinguished scientific achievement, sustained scholarly productivity, and meaningful contributions to research advancement. [1]

Abstract

Richard Schwartz is an academic researcher whose work in immunology has contributed to scientific understanding through peer-reviewed publications, interdisciplinary collaboration, and sustained research activity. His publication record, citation performance, and internationally indexed research output reflect continuing influence within the biomedical research community. The academic indicators summarized in this profile provide an overview of his scholarly contributions using publicly available bibliometric information.[1][2]

Keywords

Immunology, Biomedical Research, Immune Response, Scientific Publications, Research Impact, Citation Analysis, Molecular Biology, Academic Excellence.

Introduction

Recognition of scientific achievement commonly incorporates qualitative assessment together with bibliometric indicators such as publication output, citation performance, and the h-index. These measures assist academic institutions and professional organizations in evaluating the influence and continuity of scholarly research while considering broader scientific contributions.[3]

Research Profile

  • Affiliated with Michigan State University.
  • Primary research specialization in Immunology.
  • Author of 56 scholarly publications indexed in Scopus.
  • Research has received 1,968 citations with an h-index of 27.
  • Active participant in collaborative biomedical and immunological research.

Research Contributions

Richard Schwartz has contributed to immunology through investigations that enhance understanding of immune regulation, disease mechanisms, and biomedical applications. His research emphasizes rigorous experimental methodologies, scientific collaboration, and dissemination of findings through internationally recognized journals. These contributions have supported continued progress within immunological science and related biomedical disciplines.[2][4]

Publications

  • Peer-reviewed research articles in immunology and biomedical sciences.
  • Internationally indexed publications demonstrating sustained scientific productivity.
  • Research cited by scholars across multiple areas of biological and medical sciences.

Research Impact

The available bibliometric indicators demonstrate continued scholarly influence through publication productivity, citation performance, and recognized research visibility. Citation metrics provide quantitative evidence of scientific engagement and complement qualitative assessment of research significance within the academic community.[1][5]

Award Suitability

Based on publicly available academic indicators, Richard Schwartz demonstrates characteristics commonly associated with recognition for scientific innovation, including sustained publication activity, measurable citation impact, and contributions to immunology. Such achievements provide evidence supporting consideration for recognition within the International Molecular Biologist Awards while remaining subject to independent review and evaluation criteria.[3]

Conclusion

Richard Schwartz has established a scholarly profile characterized by consistent research productivity, internationally indexed publications, and measurable academic impact. His work in immunology contributes to the advancement of biomedical knowledge and reflects continued commitment to scientific excellence, collaboration, and responsible dissemination of research findings.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Richard Schwartz, Author ID 7404170129. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7404170129
  2. Google Scholar. (n.d.). Richard Schwartz – Google Scholar Citations.
    https://scholar.google.co.uk/citations?user=QBELV48AAAAJ&hl=en&oi=ao
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences.
    https://doi.org/10.1073/pnas.0507655102
  4. Orcid. Author details .Advances in immunological research and translational science.
    https://doi.org/10.1038/nri.2017.123
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Mona Gadallah | Microbiology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Mona Gadallah
Tanta University , Egypt

Mona Gadallah
Affiliation Tanta University
Country Egypt
Scopus ID 58328212200
Documents 5
Citations 10
h-index 2
Subject Area Microbiology
Event International Molecular Biologist Awards
Google Scholar ID B1Yd0O0AAAAJ

Mona Gadallah is a researcher affiliated with Tanta University, Egypt, specializing in Microbiology. Her academic activities focus on microbial sciences, biological research, and scientific studies contributing to advancements in life sciences. [1]

Abstract

The Innovative Research Award recognizes researchers who contribute to scientific discovery, academic development, and advancement within their specialized fields. Mona Gadallah’s research profile in Microbiology reflects engagement with biological research and scholarly activities. [2]

Keywords

  • Microbiology
  • Microbial Research
  • Biological Sciences
  • Scientific Innovation

Introduction

Microbiology studies microorganisms and their interactions with biological systems, supporting developments in healthcare, biotechnology, environmental science, and molecular research. Scientific contributions in this field help improve understanding of microbial processes. [3]

Research Profile

Mona Gadallah has developed a research profile within Microbiology through academic studies and scientific publications. The researcher has contributed to scholarly literature with published documents and citation impact in the field of microbial sciences. [1]

Research Contributions

  • Contribution to microbiological research studies.
  • Advancement of knowledge related to microorganisms.
  • Support for scientific communication through research output.

Publications

The researcher’s publications contribute to Microbiology literature by addressing biological processes and microbial investigations. These studies support continued research development in life sciences. [4]

Research Impact

Research impact is reflected through scientific publications, citations, and contributions to academic knowledge. Mona Gadallah’s work demonstrates participation in Microbiology research and scientific advancement. [2]

Award Suitability

The Innovative Research Award highlights researchers involved in meaningful scientific work and knowledge development. Mona Gadallah’s research background in Microbiology aligns with the goals of recognizing academic contributions. [5]

Conclusion

Mona Gadallah represents a researcher contributing to Microbiology through scientific investigation and academic work. Her research activities support continued exploration of microbial sciences and biological research.

References

  1. Elsevier. (n.d.). Scopus author details: Mona Gadallah, Author ID 58328212200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58328212200
  2. Google Scholar. (n.d.). Mona Gadallah Research Profile.
    https://scholar.google.com/citations?user=B1Yd0O0AAAAJ&hl=en
  3. Nature Reviews Microbiology. (n.d.). Microbiology Research Concepts.
    https://doi.org/10.1038/s41579-020-00430-0
  4. PubMed. (n.d.). Microbial Science Publications.
    https://doi.org/10.1016/j.ijbiomac.2020.01.001
  5. International Molecular Biologist Awards. (n.d.). Award Information Portal.
    https://molecularbiologist.org/

Qibin Liao | Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr. Qibin Liao | Immunology | Best Researcher Award 

Assistant Researcher, at Shenzhen Third People’s Hospital, China.

Dr. Qibin Liao (b. February 1991 🇨🇳) is a leading early-career biomedical researcher specializing in cellular immunotherapy for infections and malignancies. Currently an Assistant Researcher at Shenzhen Third People’s Hospital, affiliated with the Southern University of Science and Technology, he focuses on the development of next-generation CAR-T cell therapies. His pioneering work includes genetically engineered T-cell technologies, including multifunctional CAR-T cells for HIV-1, and novel systems for solid tumors that improve safety and efficacy. Dr. Liao’s contributions have been widely recognized in high-impact journals such as EMBO Molecular Medicine, Biomedicines, and Cell Discovery. 🧪🔬 His research continues to push the boundaries of precision immunotherapy, bridging basic science and clinical application. He has also been awarded substantial national-level research funding and plays critical roles in multiple R&D programs. Through innovative designs and clinical translation, he is reshaping the future of personalized medicine and cancer treatment. 🌍💉

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Qibin Liao began his academic journey at Southern Medical University where he earned a Bachelor of Medicine in Preventive Medicine (2010–2015). His strong foundation in public health and disease prevention laid the groundwork for his later focus on translational immunotherapy. 🚑🧠 He further advanced his training by pursuing a Ph.D. in Medical Systems Biology at Fudan University (2015–2021), one of China’s top-tier research institutions. Here, he honed his expertise in systems-level analysis and experimental techniques related to T-cell engineering and immunological signaling. His doctoral research contributed to the development of hypoxia-inducible CAR-T systems—a novel approach to improve safety and specificity in cancer therapy. 🎓💉 His interdisciplinary education spanning clinical medicine, biology, and biotechnology enables him to approach complex immunological problems with a holistic and systems-oriented mindset. This strong academic foundation underpins his contributions to advanced biomedical innovations.

💼 Professional Experience

Since October 2021, Dr. Liao has served as an Assistant Researcher at Shenzhen Third People’s Hospital, the Second Affiliated Hospital of Southern University of Science and Technology. 🏥 He is part of an elite biomedical team addressing viral infections, immune therapies, and tumor immunology. His role includes designing synthetic CAR-T constructs, leading clinical translational research, and supervising junior researchers in immunotherapy development. 💡 Before this, his graduate training involved active participation in interdisciplinary immunology and molecular biology labs at Fudan University, where he collaborated on multiple clinical and preclinical studies. His career is marked by a strategic blend of basic science and applied therapeutic innovation. Dr. Liao also serves as Principal Investigator (PI) and co-leader in several national programs funded by the National Natural Science Foundation of China and National Key R&D Program, demonstrating both scientific leadership and administrative excellence. 🧪📊

🔬 Research Interests

Dr. Liao’s research centers on cellular immunotherapy, particularly CAR-T cell technology tailored for HIV-1 and solid tumors. 💉 His key interest lies in genetic engineering of T cells to enhance therapeutic performance while minimizing toxicity. He has pioneered techniques such as the hypoxia-inducible CAR-T (HiCAR) system and PD-L1 chimeric costimulatory receptors, designed to address safety challenges in treating solid malignancies. 🧠 His research also extends to multifunctional CAR-T designs with dual antiviral and antitumor capabilities, applied in phase I clinical studies. Dr. Liao is passionate about immune microenvironment modulation, tumor-selective antigen targeting, and developing biomarker-based predictive tools for personalized therapy outcomes. 🧬 His projects integrate synthetic biology, translational immunology, and clinical oncology, making his research deeply impactful for both infectious diseases and cancer immunotherapy. His vision is to bring precision immune-engineering tools from bench to bedside. 🧑‍🔬🦠

🏆 Awards

🔹 Best Researcher Award Nomination (2025) – Selected for publication in Biomedicines (2025) for innovative CAR-T therapy targeting AXL in solid tumors.
🔹 National Natural Science Foundation of China (NSFC) – Youth Science Fund Grant (¥300,000, 2025–2027).
🔹 National Key R&D Program Grants – Totaling ¥1,125,000 as PI or task leader across two major national projects in HIV and stem cell therapy (2022–2027).
🔹 Corresponding or co-first author in top-tier journals including Cell Discovery, Journal of Advanced Research, and Biomarker Research.
🔹 Invited to multiple academic symposia and recognized for contributions to translational immunotherapy and cellular engineering.
These accolades reflect his innovative thinking, scientific rigor, and clinical impact. 🥇📚 His work continues to be spotlighted across China’s biomedical innovation ecosystem.

📚 Top Noted Publications

Dr. Liao has authored/co-authored several impactful publications. Highlights:

1. Novel mRNA-Engineered Fully Human CAR-T Cells Targeting AXL in Solid Tumors

Journal: Biomedicines
Year: 2025
Cited by: 4
Summary:

  • Introduces an mRNA-engineered CAR-T cell targeting AXL, a receptor overexpressed in many solid tumors.

  • Uses a fully human scFv to reduce immunogenicity.

  • Demonstrates promising anti-tumor effects in preclinical solid tumor models, with transient CAR expression for improved safety.

2. Safe CAR-T: Shedding Light on CAR-Related T-cell Malignancies

Journal: EMBO Molecular Medicine
Year: 2025
Cited by: 7
Summary:

  • Addresses rare but serious cases of CAR-T-cell derived T-cell malignancies.

  • Explores the integration of CAR constructs into oncogenes as a potential risk.

  • Discusses safer vector systems and genomic insertion site monitoring.

3. Efficacy and Safety of M10 CAR-T Cells in HIV-1-Infected Patients

Journal: Cell Discovery
Year: 2024
Cited by: 18
Summary:

  • Describes M10 CAR-T cells engineered to target HIV-1-infected cells.

  • First-in-human data showed viral suppression and CD4+ T-cell recovery.

  • Provides early evidence for CAR-T application in chronic viral infections.

4. Biomarkers for Predicting CAR-T Efficacy and Detection Methods

Journal: iLABMED
Year: 2024
Cited by: 6
Summary:

  • Reviews current predictive biomarkers (e.g., tumor burden, cytokine profiles, T-cell exhaustion markers).

  • Discusses liquid biopsy, single-cell RNA-seq, and digital PCR as detection methods.

  • Emphasizes personalized CAR-T strategies using biomarker profiling.

5. Mouse Model for Evaluating CAR-T On-Target Toxicity

Journal: Journal of Advanced Research
Year: 2023
Cited by: 11
Summary:

  • Presents a novel humanized mouse model to assess on-target/off-tumor toxicity of CAR-T cells.

  • Demonstrates the importance of tissue-specific antigen expression in predicting adverse effects.

  • Tool for preclinical safety validation.

6. Hypoxia-Inducible CAR-T Cells (HiTA System)

Journal: Journal for ImmunoTherapy of Cancer
Year: 2021
Cited by: 24
Summary:

  • Introduces a hypoxia-inducible switch to activate CAR-T cells only in low oxygen environments typical of solid tumors.

  • Reduces systemic toxicity while maintaining anti-tumor efficacy.

  • Demonstrates improved safety in vivo with retained tumor-killing activity.

7. PD-L1 Chimeric Receptor Improves Efficacy in Solid Tumors

Journal: Biomarker Research
Year: 2020
Cited by: 27
Summary:

  • Describes a chimeric receptor targeting PD-L1, converting immunosuppressive signals into activating signals.

  • Enhances CAR-T function in immunosuppressive microenvironments.

  • Synergistic potential with checkpoint inhibitors.

8. HiCAR for Selective Tumor Killing

Journal: Biomarker Research
Year: 2020
Cited by: 21
Summary:

  • Describes HiCAR, a system integrating tumor-specific antigens and environmental cues for precise activation.

  • Uses dual-input logic for increased specificity and reduced toxicity.

  • Aimed at improving solid tumor selectivity of CAR-T therapies.

Conclusion 

Dr. Qibin Liao is highly suitable for the Best Researcher Award. His work on CAR-T innovations for both cancer and HIV is pioneering, impactful, and clinically relevant. The blend of scientific innovation, clinical translation, and strong funding/publication record positions him among the top emerging researchers in biomedical science in China.

Shaghayegh Baradaran Ghavami | Autoimmune disease and Immunology | Best Researcher Award

Published on by Molecular Biologist

Dr.Shaghayegh Baradaran Ghavami | Autoimmune disease and Immunology | Best Researcher Award

The head of IBD lab Research Institute for Gastroenterology and Liver Disease. Shaheed Beheshti University of Medical Sciences. Tehran, Iran

Shaghayegh Baradaran Ghavami is a distinguished microbiologist and researcher at Shahid Beheshti University of Medical Sciences. She has made significant contributions to the field of inflammatory bowel diseases (IBD) through her innovative research on the gut microbiome and its implications for human health. With a strong academic background and numerous publications, she continues to advance our understanding of microbiology and its applications in medical science.

Profile

Google Scholar

Education 🎓

Shaghayegh Baradaran Ghavami holds a Clinical Research Fellowship (2020-2021) from the Research Institute for Gastroenterology and Liver Diseases at Shahid Beheshti University of Medical Sciences. She earned her Ph.D. in Microbiology from Azad University, Science and Research Branch, Tehran, Iran (2010-2015), and an MS.c in Microbiology (2008-2010) from Islamic Azad University North Tehran Branch. She completed her BS.c in Molecular and Cellular Microbiology at the same university (2000-2004).

Experience 💼

Shaghayegh has extensive experience in research and academia. She served as a Research Assistant (2016-2020), where she conducted and supervised various research projects. During her Ph.D. (2010-2015), she focused on “Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases.” Additionally, she worked as a tutor in the Microbiology department at Azad University, Medical Branch of Tehran (2010-2019), and observed research at Dr. Jeremy Burton Lab at Lawson Health Research Institute in Canada (2018).

Research Interests 🔬

Shaghayegh’s research interests lie in microbiology, specifically in studying the gut microbiome’s role in inflammatory bowel diseases and other gastrointestinal disorders. Her work focuses on the interplay between host genetic polymorphisms and microbial communities, aiming to uncover novel biomarkers and therapeutic targets for IBD and related conditions.

Awards 🏆

Shaghayegh has been recognized for her contributions to science, including receiving a $30,000 grant from Orchid Life Company for her IBD & COVID-19 project in May 2020. She has also been nominated for various academic awards for her groundbreaking research.

Publications 📚

  1. Kazemifard N, Farmani M, Baradaran Ghavami Sh, et al. A prediction of the CRNDE role by modulating NF-κB pathway in inflammatory bowel disease (IBD). BB Rreports. 2024 May. https://doi.org/10.1016/j.bbrep.2024.101731.
  2. Vaezi Z, Baradaran Ghavami Sh, Farmani, et al. Oral Formulation of 5-Aminosalicylic Acid-Hemoglobin Bio-Adhesive Nanoparticles Enhance Therapeutic Efficiency in Ulcerative Colitis Mice: A Preclinical Evaluation. J Pharm Sci. 2024 Apr 4. https://doi.org/10.1016/j.xphs.2024.03.028.
  3. Basiji K, Sendani AA, Baradaran Ghavami Sh, et al. The critical role of gut-brain axis microbiome in mental disorders. Metab Brain Dis. 2023. https://doi.org/10.1007/s11011-023-01248-w.
  4. Khazdouz M, Daryani NE, Cheraghpour M, Baradaran Ghavami Sh, et al. The effect of selenium supplementation on disease activity and immune-inflammatory biomarkers in patients with mild-to-moderate ulcerative colitis: a randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. 2023. https://doi.org/10.1007/s00394-023-03214-9.
  5. Asadzadeh-Aghdaei H, Rejali L, Nourian M, Chaleshi V, Zamani N, Baradaran Ghavami Sh, et al. Toll-like Receptor 7 is a novel non-invasive inflammatory genetic sensor for ulcerative colitis remission monitoring. Adv Biomed Res. 2023 Feb 25. https://doi.org/10.4103/abr.abr_24_22.
  6. Hatamnejad MR, Karvandi M, Jodatfar F, Ebrahimi N, Baradaran Ghavami Sh, et al. Evaluation of adalimumab effects on left ventricle performance by echocardiography indexes among patients with immunosuppressant refractory ulcerative colitis. Front Med. 2023. https://doi.org/10.3389/fmed.2022.1008711.
  7. Hatamnejad MR, Baradaran Ghavami Sh, Marzieh Shirvani, et al. Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.980189.
  8. Kazemifard N, Dehkohneh A, Baradaran Ghavami Sh. Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy. Front Med. 2022. https://doi.org/10.3389/fmed.2022.940454.
  9. Rajabnia M, Hajimirzaei SM, Hatamnejad MR, Baradaran Ghavami Sh, et al. Obesity is a challenge in the management of inflammatory bowel diseases. Immunol Res. 2022. https://doi.org/10.1007/s12026-022-09315-7.
  10. Mobin Makhmalbaf, Seyed Masoud Hosseini, Hamid Asadzadeh Aghdaei, Baradaran Ghavami Sh, et al. Detection of SARS-CoV-2 Genome in Stool and Plasma Samples of Laboratory Confirmed Iranian COVID-19. Front Mol Biosci. 2022. https://doi.org/10.3389/fmolb.2022.865129.
  11. Khoramjoo SM, Kazemifard N, Baradaran Ghavami Sh, Farmani M, Shahrokh S, Asadzadeh Aghdaei H, Sherkat G, Zali MR. Overview of Three Proliferation Pathways (Wnt, Notch, and Hippo) in Intestine and Immune System and Their Role in Inflammatory Bowel Diseases (IBDs). Front Med (Lausanne). 2022. https://doi.org/10.3389/fmed.2022.865131.